Compare DTIL & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DTIL | LXEO |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.6M | 348.7M |
| IPO Year | 2019 | 2023 |
| Metric | DTIL | LXEO |
|---|---|---|
| Price | $7.35 | $2.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $29.40 | $25.11 |
| AVG Volume (30 Days) | 402.8K | ★ 2.5M |
| Earning Date | 11-03-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000,000.00 | $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.53 | $2.55 |
| 52 Week High | $11.29 | $10.99 |
| Indicator | DTIL | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 47.03 |
| Support Level | $6.12 | $2.72 |
| Resistance Level | $7.80 | $3.56 |
| Average True Range (ATR) | 0.93 | 0.41 |
| MACD | -0.22 | 0.02 |
| Stochastic Oscillator | 17.63 | 16.56 |
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.